TECX · Tectonic Therapeutic, Inc.
Market Cap
$584.92M
Shares
19.55M
TECX metrics
52 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$29.92
Market cap
$584.92M
Price action
19 metricsPrice change (1W)
-18.5%
Price change (30D)
+1.2%
Price change (3M)
+2.7%
Price change (6M)
+7.4%
Price change (YTD)
+43.4%
Price change (1Y)
+83.2%
Trailing year
Price change (5Y)
—
52-week high
$37.93
52-week low
$14.71
Change from 52-week high
-21.1%
Change from 52-week low
+103.4%
Annualized volatility
76.4%
Beta
1.1
RSI (14D)
41.1
Price vs SMA 50
-9.3%
Price vs SMA 200
+9.6%
Avg volume (3M)
195,332
Relative volume
0.7
Average dollar volume
$6.44M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
19.55M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.6
reciprocal yield 38.3%
FCF yield
-12.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-14.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-02-24
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$94.92M
Net income (TTM)
−$85.79M
Trailing 12 months
Diluted EPS (TTM)
$-4.57
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-38.3%
Return on assets
-36.2%
Debt / equity
—
Current ratio
22.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$72.42M
Quick ratio
22.3
Interest coverage
-2,373.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$227.07M
Total assets
$237.03M
Total debt
$15.00M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$72.14M
Capital expenditures (TTM)
$279,000
R&D (TTM)
$72.19M
SG&A (TTM)
—
Stock compensation (TTM)
$13.02M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
124
13F filer change QoQ
+11
Institutional ownership
72.5%
Short interest
3 metricsShort interest
8.8%
Latest settlement · 8.4 days to cover
Days to cover
8.4d
Short-squeeze score
63 / 100
Insider activity
2 metricsNet insider buying (90D)
−$9,095
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1681087
CUSIP
878972108
13F (30d)
103 filings
103 filers
Visit website
Investor relations